Targeted Oncology16m
Durvalumab Wins FDA Approval in Limited-Stage Small Cell Lung Cancer
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
Targeted Oncology3h
Real-World Outcomes of Lenvatinib in RAI-Refractory Differentiated Thyroid Cancer
Francis P. Worden, MD, discusses how the effectiveness of lenvatinib in this real-world setting compares with results from ...
Targeted Oncology3h
FDA Grants Breakthrough Status to Sacituzumab Tirumotecan in EGFR+ NSCLC
The FDA granted breakthrough therapy status to sacituzumab tirumotecan in EGFR-mutated advanced non–small cell lung cancer.
Targeted Oncology5h
Novel Sonodynamic Therapy Doubles Survival in Recurrent Glioblastoma
Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...
Targeted Oncology7h
DSMB Approves Continued GOBLET Cohort 5 Enrollment in Pancreatic Cancer
Enrollment in cohort 5 of the phase 1/2 GOBLET study will resume after the Data Safety Monitoring Board’s safety review.
Targeted Oncology9h
Daratumumab Quadruplet Improves Outcomes in Transplant-Ineligible Myeloma
Saad Z. Usmani, MD, MBA, FACP, FASCO, discusses the CEPHEUS trial results and impact on frontline treatment in ...
Targeted Oncology23h
Zenocutuzumab Now FDA-Approved in NRG1+ NSCLC and Pancreatic Cancer
The FDA has approved zenocutuzumab, making it the first and only approved targeted therapy for patients with NRG1+ NSCLC and ...